CC BY 4.0 · Nuklearmedizin
DOI: 10.1055/a-1659-0010
Review

[18F]DCFPyL PET/CT for Imaging of Prostate Cancer

[18F]DCFPyL PET/CT zur Prostatakarzinom-Bildgebung
Steven P. Rowe
1  The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, United States
2  Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, United States
3  Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, United States
,
Andreas Buck
4  Nuclear Medicine, Würzburg University Medical Center Clinic for Nuclear Medicine, Würzburg, Germany (Ringgold ID: RIN526288)
,
Ralph A. Bundschuh
5  Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany (Ringgold ID: RIN39062)
,
Constantin Lapa
6  University of Augsburg, Augsburg, Germany (Ringgold ID: RIN26522)
,
Sebastian E. Serfling
4  Nuclear Medicine, Würzburg University Medical Center Clinic for Nuclear Medicine, Würzburg, Germany (Ringgold ID: RIN526288)
,
Thorsten Derlin
7  Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany
,
Takahiro Higuchi
4  Nuclear Medicine, Würzburg University Medical Center Clinic for Nuclear Medicine, Würzburg, Germany (Ringgold ID: RIN526288)
8  Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
,
Michael A. Gorin
9  Urology Associates and UPMC Western Maryland, Cumberland, United States
10  Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, United States
,
Martin G. Pomper
1  The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, United States
2  Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, United States
3  Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, United States
,
Rudolf A. Werner
4  Nuclear Medicine, Würzburg University Medical Center Clinic for Nuclear Medicine, Würzburg, Germany (Ringgold ID: RIN526288)
› Author Affiliations
Supported by: “RECTOR” Program at Okayama RECTOR

Abstract

Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, 68Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of 18F-labeled agents. Among others, [18F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [18F]DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this 18F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [18F]DCFPyL in various clinical settings for men with PC.

Zusammenfassung

Die Positronen-Emissions-Tomografie (PET) mit PSMA (Prostata-spezifisches Membran-Antigen) gerichteten Liganden ist zunehmend in den Fokus der Bildgebung des Prostatakarzinoms (PC) bei Männern gerückt. In den letzten Jahren wurden in großem Umfang 68Ga-markierte PSMA-Tracer verwendet, obwohl ein Trend zum verstärkten Einsatz von 18F-markierten Tracern zu beobachten ist. Unter anderem wurde [18F]DCFPyL (Piflufolastat F 18, PYLARIFY) in mehreren großen Studien wie OSPREY und CONDOR untersucht, die eine belastbare Evidenz für den klinischen Nutzen dieses Tracers hinsichtlich Staging, Restaging und Änderung des Managements zeigten. Neuere prospektive Untersuchungen haben [18F]DCFPyL PET/CT auch zur Beurteilung des Ansprechens eingesetzt, z. B. bei Patienten unter Abirateron oder Enzalutamid, was diesen 18F-markierten PSMA-Radiotracer zu einem attraktiven Biomarker für bildgestützte Strategien bei Männern mit PC macht. Nach der kürzlich erfolgten Zulassung durch die U.S. Food and Drug Administration (FDA) ist nicht nur in den USA, sondern langfristig auch in Europa mit einer breiteren Anwendung zu rechnen. Im vorliegenden Review geben wir einen Überblick über den aktuellen klinischen Nutzen von [18F]DCFPyL bei Männern mit PC in verschiedenen klinischen Situationen.



Publication History

Received: 12 September 2021

Accepted: 17 September 2021

Publication Date:
14 January 2022 (online)

© 2022. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany